Resveratrol synthase uncovered: Cyclization specificity of type III polyketide synthases
A group from the Salk institute illuminates the structural basis for tetraketide cyclization in stilbene synthase, the enzyme that produces resveratrol, the beneficial phytonutrient found in red wine.... ...Plant natural products called stilbenes can confer antifungal resistance to host plants and have been shown to possess health benefits for humans and other animals when present in their d...OneWorld Health completes enrollment, treatment in Phase III India trial
San Francisco, Calif. May 18, 2004 The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., announced today it has completed enrollment and treatment of 667 patients in India suffering from visceral leishmaniasis (VL), a deadly parasitic disease also known as kala azar. Funded largely by the Bill & Melinda Gates Foundation, the largest Phase III clinical trial...Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
Investigators involved in the pivotal clinical trial of Tectin ......Tectin, a drug derived from the puffer fish, also known as blow fish or fugu, ...has been developed by Vancouver-based International Wex Technologies Inc. to block slow sodium channel nocicipetive pain fibers in a h...Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
Genentech, Inc. and XOMA Ltd. today announced positive results from a randomized Phase III clinical trial with Raptiva (efalizumab) that studied efficacy and safety in the treatment of adults with moderate-to-severe plaque psoriasis. The study results were presented by Kenneth Gordon, M.D., Associate Professor of Medicine, Division of Dermatology at Loyola University in Chicago, Illinois during...Phase III, 48-Wk NEAT study results comparing GW433908 to Nelfinavir presented today
Boston (Feb. 14, 2003) Final 48-week results from the NEAT trial, an open-label, multi-center study evaluating the safety and efficacy of the investigational protease inhibitor (PI) GW433908 (908) in antiretroviral therapy-nave HIV+ patients versus nelfinavir (NFV/Viracept), were presented here today. In the trial, 66 percent of 166 HIV+ patients (n=109) achieved an undetectable viral load (vRN...Hemophilia therapy update: New information on investigational Factor VIII therapy development
WEBCAST INVITATION...... Hemophilia Therapy Update: New Information on Investigational Factor VIII Therapy Development...... ...12:30 1:30 EST ...Loews Philadelphia Hotel, Commonwealth Hall A...... AGENDA...... ...Joe Caronna, Vice President, New Jersey Hemophilia Association, and Father of Patient with Hemophilia A...... ...W. Keith Hoots, M.D., Medical Director, Gulf States Hemophilia and Thro...PRAECIS announces positive results for abarelix depot-M in two pivotal Phase III clinical trials
. New Orleans, LA, May 23, 2000. - PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced the results of two Phase III studies for its lead compound, abarelix depot-M, for the treatment of prostate cancer. PRAECIS is developing this product globally with its corporate collaborators. These two studies, which included 520 prostate cancer patients, showed the intended benefits of ab...Abgenix initiates phase III clinical trial of graft versus host disease therapy
. . . . . Abgenix to Seek a Corporate Partner to Commercialize ABX-CBL . . FREMONT, Calif., December 7, 1999 - Abgenix, Inc. (Nasdaq: ABGX) is initiating a Phase III. clinical trial comparing its antibody, ABX-CBL, with standard therapy for patients with. steroid-resistant graft-versus-host disease (srGVHD), a serious, life-threatening disorder. Abgenix. also indicated that it would seek a....Vanderbilt University Medical Center scientists deciphered how the Type III.TGF-beta receptor leads to the formation of valves and dividing walls in the.heart, reports the March 26th issue of Science.. .Their findings have particular relevance to the families of children with.congenital heart defects, the leading cause of birth defect-related deaths. .About 1 in 100 children born each year in t...... ...Positive Results of Phase I Study Presented ...At American College of Cardiology Conference ... ...SEATTLE -- Immunex Corporation (NASDAQ:IMNX and Wyeth-Ayerst Laboratories...announced today that they are beginning a Phase II/III clinical trial with...ENBREL (etanercept) in chronic heart failure patients, one of the first...large-scale studies undertaken to evaluate cy....San Diego, CA, September 27, 1998 - Clinical investigators today presented.Phase III clinical trial data for the HIV protease inhibitor Agenerase`.(amprenavir) which suggest that the drug may be potent and generally.well-tolerated in combination with Epivir" (lamivudine) also known as 3TC",.and Retrovir" (zidovudine; AZT). These data, presented at a late-breaker.slide session at the 38th Inter...